Results 21 to 30 of about 21,587 (248)

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]

Aliment Pharmacol Ther
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS, Kwo P, Pappas SC, O'Leary JG, Jamil K, Cardoza S, Wong F.   +6 more
europepmc   +2 more sources

The hepatorenal syndrome [PDF]

Gut, 2001
Introduction The hepatorenal syndrome (HRS) is defined as the development of renal failure in patients with severe liver disease (acute or chronic) in the absence of any other identifiable cause of renal pathology. It is diagnosed following exclusion of other causes of renal failure in patients with liver disease such as hypovolaemia, drug ...
L, Dagher, K, Moore
openaire   +2 more sources

Necessity and feasibility of developing diagnosis and treatment guidelines for  cirrhotic ascites and hepatorenal syndrome with Chinese intellectual property rights

Zhongguo linchuang yanjiu, 2023
At pressent, there are many controversies in China about the recommendations in Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome (hereinafter referred to as the “Guidelines”) revised in 2021 ...
LIU Jianjun, ZHENG Wenkai, GAO Tingting, WANG Jianghong, REN Yanjun, LIU Jianguo, LIU Changlin   +6 more
doaj   +1 more source

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P, Arroyo V, BERNARDI, MAURO, Blendis L, Di Bona G, Garcia Tsao G, Gerbes A, Ginès P, Guevara M, Gülberg V, Henriksen JH, Kamath P, Lee S, Moore K, Moreau R, Mullen K, Ortega R, Ruiz del Arbol L, Salerno F, Sanyal A, Terg R., Wong F   +21 more
core   +4 more sources

Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study [PDF]

, 2012
Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease.
Bachmann, Malte, Brunner, Friederike, Filmann, Natalie, Herrmann, Eva, Kapper, Lisa, Kronenberger, Bernd, Mühl, Heiko, Pfeilschifter, Josef Martin (Prof. Dr.), Piiper, Albrecht, Rudloff, Ina, Waidmann, Oliver, Zeuzem, Stefan   +11 more
core   +1 more source

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

Frontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud, Doaa H Abdelaziz, Doaa H Abdelaziz, Sherief Abd-Elsalam, Noha O. Mansour   +4 more
doaj   +1 more source

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]

, 2017
Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V., Boyer, T. D., Escalante, S., Frederick, R. T., Jamil, K., Pappas, S. C., Reddy, K. R., Rossaro, L., Sanyal, A. J., Teuber, P., Vargas, H. E., Wong, F.   +11 more
core   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Low doses of terlipressin and albumin in the type I hepatorenal syndrome

Italian Journal of Medicine, 2013
BACKGROUND Hepatorenal syndrome is a pre-renal like dysfunction that generally onsets in cirrhotic patients presenting ascites. MATERIALS AND METHODS We investigated the improvement of renal function in subjects with hepatorenal syndrome after ...
Davide Pulvirenti, Aikaterini Tsami
doaj   +1 more source